CN119241504A - Kif18a的螺吲哚啉抑制剂 - Google Patents

Kif18a的螺吲哚啉抑制剂 Download PDF

Info

Publication number
CN119241504A
CN119241504A CN202411174936.6A CN202411174936A CN119241504A CN 119241504 A CN119241504 A CN 119241504A CN 202411174936 A CN202411174936 A CN 202411174936A CN 119241504 A CN119241504 A CN 119241504A
Authority
CN
China
Prior art keywords
alkyl
halo
group
cycloalkyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411174936.6A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·柯根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Volascha Therapy Co
Original Assignee
Volascha Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Volascha Therapy Co filed Critical Volascha Therapy Co
Priority claimed from CN202280069468.9A external-priority patent/CN118103352A/zh
Publication of CN119241504A publication Critical patent/CN119241504A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202411174936.6A 2021-08-26 2022-08-25 Kif18a的螺吲哚啉抑制剂 Pending CN119241504A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163237275P 2021-08-26 2021-08-26
US63/237,275 2021-08-26
US202263306452P 2022-02-03 2022-02-03
US63/306,452 2022-02-03
US202263344435P 2022-05-20 2022-05-20
US63/344,435 2022-05-20
PCT/US2022/075472 WO2023028564A1 (en) 2021-08-26 2022-08-25 Spiro indoline inhibitors of kif18a
CN202280069468.9A CN118103352A (zh) 2021-08-26 2022-08-25 Kif18a的螺吲哚啉抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280069468.9A Division CN118103352A (zh) 2021-08-26 2022-08-25 Kif18a的螺吲哚啉抑制剂

Publications (1)

Publication Number Publication Date
CN119241504A true CN119241504A (zh) 2025-01-03

Family

ID=83457176

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202411174936.6A Pending CN119241504A (zh) 2021-08-26 2022-08-25 Kif18a的螺吲哚啉抑制剂

Country Status (12)

Country Link
US (2) US12084420B2 (https=)
EP (1) EP4392407A1 (https=)
JP (1) JP2024534840A (https=)
KR (1) KR20240109977A (https=)
CN (1) CN119241504A (https=)
AU (1) AU2022334480A1 (https=)
CA (1) CA3230123A1 (https=)
CL (1) CL2024000560A1 (https=)
IL (1) IL310863A (https=)
MX (1) MX2024002391A (https=)
TW (1) TW202317092A (https=)
WO (1) WO2023028564A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI844602B (zh) 2018-12-20 2024-06-11 美商安進公司 Kif18a抑制劑
TW202416973A (zh) 2022-08-18 2024-05-01 美商雅客森醫療公司 Ｋｉｆ１８ａ抑制劑及其用途
WO2024066986A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物
CN120202002A (zh) * 2022-11-30 2025-06-24 微境生物医药科技(上海)有限公司 一种用于癌症治疗的药物组合物
EP4669309A1 (en) * 2023-02-23 2025-12-31 Volastra Therapeutics, Inc. SOLID FORMULATIONS AND POLYMORPHIC FORMS OF KIF18A INDOLIN INHIBITORS
WO2024188338A1 (zh) * 2023-03-16 2024-09-19 微境生物医药科技(上海)有限公司 Kif18a抑制剂
CN121909029A (zh) 2023-06-14 2026-04-21 沃拉斯查疗法公司 用kif18a的吲哚啉抑制剂治疗癌症的方法
WO2025190325A1 (zh) * 2024-03-13 2025-09-18 海南先声再明医药股份有限公司 Kif18a抑制剂和微管蛋白抑制剂的药物组合及用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6534309B1 (en) 2000-08-03 2003-03-18 Cytokinetics, Inc. Motor proteins and methods for their use
AU2002231098A1 (en) 2000-12-15 2002-06-24 Emory University Nonpeptide agonists and antagonists of vasopressin receptors
WO2004039774A2 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
EP2305812A3 (en) 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7423018B2 (en) 2002-12-13 2008-09-09 University Of Massachusetts Kinesin-like proteins and methods of use
AU2004264533B2 (en) 2003-08-15 2009-01-22 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
US7504413B2 (en) 2004-05-06 2009-03-17 Cytokinetics, Inc. N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases
KR101170925B1 (ko) 2004-06-18 2012-08-07 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 암 치료용 키네신 방추 단백질 (ｋｓｐ) 억제제로서의ｎ-(1-(1-벤질-4-페닐-1ｈ-이미다졸-2-일)-2,2-디메틸프로필)벤자미드 유도체 및 관련 화합물
ATE486878T1 (de) 2004-08-18 2010-11-15 4Sc Ag Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
US7829296B2 (en) 2005-04-25 2010-11-09 Ramot At Tel-Aviv University Ltd. Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same
JP2009514866A (ja) 2005-11-02 2009-04-09 サイトキネティクス・インコーポレーテッド ある種の化学物質、組成物、および方法
WO2008007122A2 (en) 2006-07-14 2008-01-17 Astex Therapeutics Limited Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
US20080051463A1 (en) 2006-08-04 2008-02-28 Aeterna Zentaris Gmbh Anthracene compounds and their use for treating benign and malignant tumor disorders
AR062200A1 (es) 2006-08-04 2008-10-22 Aeterna Zentaris Gmbh Derivados de antraceno y su uso para el tratamiento de emfermedades tumorales bengnas y malingnas
AR077033A1 (es) 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
EP2295543A1 (en) 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
WO2011085261A1 (en) 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
JP5111626B2 (ja) 2011-01-14 2013-01-09 Ｎｔｎ株式会社 電動シートリクライニング用ころ軸受
CN102796103A (zh) 2011-05-23 2012-11-28 南京英派药业有限公司 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
JP6098406B2 (ja) 2013-07-17 2017-03-22 Ｊｆｅスチール株式会社 溶接接合部および溶接接合方法
PT3031799T (pt) 2013-08-09 2018-07-04 Takeda Pharmaceuticals Co Composto aromático
WO2015183776A1 (en) 2014-05-29 2015-12-03 Merck Sharp & Dohme Corp. Methods for treating cancer with a wee1 inhibitor
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
TW201643139A (zh) * 2015-04-17 2016-12-16 佛瑪治療公司 作為組蛋白脫乙醯基酶抑制劑之３－螺環－６－異羥肟酸萘滿
WO2016177340A1 (zh) 2015-05-05 2016-11-10 上海海雁医药科技有限公司 双环取代的苯磺酰胺衍生物、其制法与医药上的用途
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
AU2017236431A1 (en) 2016-03-24 2018-09-27 Bayer Pharma Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
SG11202000132WA (en) 2017-07-10 2020-02-27 Univ Cornell Targeting chromosomal instability and downstream cytosolic dna signaling for cancer treatment
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN108768023B (zh) 2018-08-13 2020-01-07 珠海格力电器股份有限公司 转子组件及交替极电机
DE102018213662A1 (de) 2018-08-14 2020-02-20 Robert Bosch Gmbh Lautsprecher mit einem darin enthaltenen Leuchtelement
CN109039072B (zh) 2018-08-21 2020-09-08 南京南瑞继保电气有限公司 一种双极双向直流变换器及其控制方法和控制装置
JP7676308B2 (ja) * 2018-12-20 2025-05-14 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
WO2020132651A1 (en) * 2018-12-20 2020-06-25 Amgen Inc. Kif18a inhibitors
EP3898616B1 (en) * 2018-12-20 2024-10-02 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
TWI844602B (zh) 2018-12-20 2024-06-11 美商安進公司 Kif18a抑制劑
EP4600650A3 (en) 2019-04-05 2025-11-26 Earli Inc. Improved methods and compositions for synthetic biomarkers
CN113785076B (zh) 2019-05-03 2024-06-11 株式会社递希真 预测癌症预后的方法及其组合物
WO2021011634A1 (en) 2019-07-15 2021-01-21 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2020326627B2 (en) * 2019-08-02 2026-01-29 Amgen Inc. KIF18A inhibitors
EP4007756B1 (en) * 2019-08-02 2025-12-24 Amgen Inc. Kif18a inhibitors
WO2021026099A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
US12540129B2 (en) * 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
WO2021161323A1 (en) 2020-02-16 2021-08-19 Genetikaplus Ltd. Methods of therapeutic prognostication
US12187992B2 (en) 2020-02-19 2025-01-07 The Regents Of The University Of California Method and device for early cancer screening
JP2023521802A (ja) 2020-04-14 2023-05-25 アムジエン・インコーポレーテツド 新生物疾患の処置のためのｋｉｆ１８ａ阻害剤
US20230233565A1 (en) 2020-05-11 2023-07-27 University Of Vermont A treatment approach involving kif18a inhibition for chromosomally unstable tumors
WO2022032073A2 (en) 2020-08-07 2022-02-10 Casma Therapeutics, Inc. Trpml modulators
EP4319821A1 (en) 2021-04-09 2024-02-14 Nanjing University Conjugate and the preparing method and use thereof
CN113528509A (zh) 2021-06-01 2021-10-22 释科生物科技(广州)有限公司 一种用于预测胃癌免疫治疗的肿瘤微环境评分系统的构建方法以及分子探针
JP7773801B2 (ja) 2021-06-25 2025-11-20 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｋｉｆ１８ａ阻害剤としての化合物
TW202321213A (zh) 2021-07-21 2023-06-01 美商安進公司 Ｋｉｆ１８ａ抑制劑化合物之鹽和固態形式
CN115772159A (zh) 2021-09-06 2023-03-10 微境生物医药科技(上海)有限公司 Kif18a抑制剂
CN115785068A (zh) 2021-09-10 2023-03-14 微境生物医药科技(上海)有限公司 Kif18a抑制剂
WO2023041055A1 (zh) 2021-09-16 2023-03-23 微境生物医药科技(上海)有限公司 Kif18a抑制剂
US20230117405A1 (en) 2021-09-22 2023-04-20 Volastra Therapeutics, Inc. Systems and methods for evaluation of chromosomal instability using machine-learning
AU2022389558A1 (en) 2021-11-19 2024-05-23 Wigen Biomedicine Technology (shanghai) Co., Ltd. Kif18a inhibitor
JP2025515484A (ja) 2022-04-28 2025-05-15 ヴォラストラ セラピューティクス，インコーポレーテッド Ｋｉｆ１８ａを阻害するための化合物

Also Published As

Publication number Publication date
IL310863A (en) 2024-04-01
EP4392407A1 (en) 2024-07-03
CA3230123A1 (en) 2023-03-02
WO2023028564A1 (en) 2023-03-02
TW202317092A (zh) 2023-05-01
US20230147507A1 (en) 2023-05-11
MX2024002391A (es) 2024-06-03
KR20240109977A (ko) 2024-07-12
US20240351984A1 (en) 2024-10-24
AU2022334480A1 (en) 2024-03-07
JP2024534840A (ja) 2024-09-26
CL2024000560A1 (es) 2024-09-13
US12084420B2 (en) 2024-09-10

Similar Documents

Publication Publication Date Title
CN119241504A (zh) Kif18a的螺吲哚啉抑制剂
CN105814048B (zh) 作为tnf活性调节剂的稠合三环苯并咪唑衍生物
CN105814055B (zh) 作为tnf活性调节剂的稠合咪唑和吡唑衍生物
CN101687827B (zh) 环状基团取代的氨基二氢噻嗪衍生物
KR20240062147A (ko) P53의 돌연변이체를 표적으로 하는 화합물
CN105814051B (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
JP2023524821A (ja) Ｅｎｐｐ１のイミノスルファノン阻害剤
NZ760657A (en) Bicyclic heterocyclyl derivatives as irak4 inhibitors
KR20100099742A (ko) 안드로겐 수용체 관련 병태의 치료에서 사용하기 위한 이환식 유도체
CN105829307A (zh) 用作tnf活性调节剂的四氢咪唑并吡啶衍生物
WO2015110999A1 (en) Ezh2 inhibitors and uses thereof
TW202346288A (zh) 用於抑制ｋｉｆ１８ａ之化合物
CN108137588B (zh) 三环稠合吡啶-2-酮衍生物及其作为brd4抑制剂的用途
KR20200083528A (ko) 파르네소이드 x 수용체 조정제로서의 스피로시클릭 화합물
US20230027198A1 (en) Inhibitors of enl/af9 yeats
KR20160065950A (ko) 열 충격 전사인자 1의 억제제로서 융합된 1,4-디히드로디옥신 유도체
EP2976341A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
CN105189508B (zh) 作为janus激酶抑制剂的环烷基腈吡唑并吡啶酮
IL300048A (en) Heterocyclic compounds with three rings, their preparation and use
KR20200083529A (ko) 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물
WO2024026484A2 (en) Cdk2 inhibitors and methods of using the same
WO2024026486A2 (en) Cdk2 inhibitors and methods of using the same
KR20190057388A (ko) Ror 감마 조정제로서의 트리시클릭 술폰
TW202440091A (zh) Ｎａｍｐｔ調節劑
CN115515959B (zh) 用作tead结合剂的三环杂环

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination